FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma By Ogkologos - May 20, 2026 161 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Boy Born With Heart Defect Gets Surgery To Help It Triple... December 26, 2021 Workout Wednesday – Leg Stretches Part 1 July 8, 2020 Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a... June 12, 2024 Lawmaker Dad Raises Awareness For RSV, An Illness He’d Never Heard... November 20, 2019 Load more HOT NEWS Neoadjuvant Docetaxel, Oxaliplatin, and S-1, as Part of Perioperative Chemotherapy, Prolongs... Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases Woman Who Lost Husband to Male Breast Cancer Goes on Road... Tratamiento agnóstico contra el cáncer: perspectiva de un experto
